SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Realty Income Corporation entered into a purchase agreement to issue and sell €600.0 million aggregate principal amount of 3.625% Notes due 2032 to underwriters led by Barclays Bank PLC, BNP PARIBAS, RBC Europe Limited, Banco Santander, and Wells Fargo Securities International Limited, with anticipated closing on July 7, 2026. This is a material debt issuance creating a new direct financial obligation.
View raw filing on EDGAR →The exhibit announces approval of material amendments to the Company's 9.875% senior secured bonds (US$150.0 million nominal), including release of ship mortgages converting the bonds from secured to unsecured, removal of use-of-proceeds restrictions, and an increase in the minimum liquidity covenant from US$20.0 million to US$30.0 million. While technically an amendment rather than a new issuance, the restructuring materially alters the Company's direct financial obligations and capital structure, warranting classification as a debt-related event. The amendment fee of 0.325% and the shift from secured to unsecured status are material to investors assessing the Company's leverage and creditworthiness.
View raw filing on EDGAR →The Fund priced and is issuing $400 million in aggregate principal amount of 6.500% Notes due 2031 in a private placement. This is a creation of a new direct financial obligation—a debt issuance—which is material to investors as it represents a significant capital raise and increases the Fund's leverage. The disclosure explicitly states the offering price, maturity date, interest rate, and expected closing date, all hallmarks of a debt issuance event under Item 2.03 (or disclosed here under Item 8.01).
View raw filing on EDGAR →This press release announces FDA Fast Track designation for SAT-3247 in Duchenne muscular dystrophy, a regulatory milestone that accelerates development and review timelines. While not a discrete M&A, financing, or personnel event, the Fast Track designation—combined with existing Orphan Drug and Rare Pediatric Disease designations—materially advances the clinical program's regulatory pathway and represents a significant operational/strategic achievement for a clinical-stage biotech company. The designation is material to investors assessing the company's progress toward commercialization.
View raw filing on EDGAR →BioCryst's Board approved a plan on June 25, 2026 to discontinue internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence facility by end of 2026, involving employee termination benefits, severance, and a strategic shift toward external innovation. The restructuring resulted in improved 2026 non-GAAP operating expense guidance from $450–$470M to $420–$440M.
View raw filing on EDGAR →This is an announcement of Golar LNG's Q2 2026 financial results release scheduled for August 13, 2026, with details on how to access the webcast presentation and conference call. Although the exhibit itself is a procedural notice rather than the results document itself, it announces the imminent disclosure of quarterly financial results, which is a material event that would affect investor assessment of the registrant's financial performance and position.
View raw filing on EDGAR →This press release announces positive real-world clinical data from a 462-patient study showing 83.5% response rate in comorbid PTSD and MDD patients treated with Deep TMS. While the data is preliminary and not yet FDA-cleared for these indications, the announcement of significant clinical evidence supporting the company's core product platform in a large patient population represents a material operational/clinical milestone that would affect investor assessment of the company's pipeline and commercial prospects. The study is the "largest real-world analysis" to date in this patient population, strengthening the clinical evidence base for the company's technology.
View raw filing on EDGAR →This is a transparency notification disclosing that Madison Avenue Partners crossed the 5% voting-rights threshold in Lakefront Biotherapeutics on June 15, 2026, acquiring 3,498,892 voting rights (5.31% of outstanding shares). While not a traditional governance event like an executive appointment or board change, this is a material shareholder disclosure under Belgian transparency legislation that would affect a reasonable investor's assessment of ownership structure and potential control dynamics. The event is governance-related (shareholder notification) but does not fit the specific named categories, making `governance_other` the appropriate classification.
View raw filing on EDGAR →The filing announces receipt of $43 million in additional orders for Sidewinder ESA terminals from a major in-flight connectivity service provider, with deliveries planned over 18 months. This represents a material operational and commercial milestone—a significant customer order that validates product demand and supports business growth—but does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or financial obligation). The order is material to a reasonable investor assessing the registrant's revenue trajectory and market position.
View raw filing on EDGAR →RedHill Biopharma filed a prospectus supplement on June 29, 2026 to increase the maximum aggregate offering amount of American Depositary Shares under an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. An ATM offering is an unregistered or registered equity issuance program that allows continuous sale of shares at market prices, which is dilutive to existing shareholders. This is a material capital-raising event typical of small- and mid-cap biotech companies.
View raw filing on EDGAR →This is an investor presentation disclosing Perion's strategic positioning, product roadmap (Perion One platform and Outmax AI agent), financial guidance for 2026 (Contribution ex-TAC $215M–$235M, Adjusted EBITDA $50M–$54M), and multiple new partnership announcements (Amazon DSP, Walmart Connect, Mastercard, Best Buy Canada, Albertsons, McSorely/Mediamark). While it contains forward-looking statements and operational metrics, it is fundamentally a strategic and business development disclosure rather than a discrete event (M&A, executive change, earnings release, or financial restatement). The partnerships and platform developments are material to investor assessment of the company's growth trajectory and competitive positioning, but the exhibit is primarily a presentation of ongoing business strategy and operational progress rather than a single material event.
View raw filing on EDGAR →Kenon announces a favorable ICSID arbitration decision in which an ad hoc committee dismissed Peru's annulment application and upheld the October 2023 Award of approximately $110.7 million in damages plus $5.1 million in fees and costs, with accrued interest totaling approximately $200 million. This is a material resolution of a significant international investment dispute with substantial financial consequences ($93 million estimated net to Kenon after capital provider arrangements and interest accrual).
View raw filing on EDGAR →The 6-K discloses results of an Annual General Meeting of Shareholders held on June 29, 2026, where shareholders approved five resolutions: re-election of four directors (Gillon Beck, Jacob Berman, Tom Overwijn, and Kelli Roiter) and appointment of Ernst & Young LLP as auditor. This is a classic shareholder_vote_results disclosure reporting the outcomes of a formal shareholder vote at an annual meeting.
View raw filing on EDGAR →Mr. Gad Dovev, Chairperson of the Audit Committee and Compensation Committee and Board member, has notified the Company of his resignation effective August 1, 2026. The disclosure explicitly states his departure is for personal reasons with no disagreement on Company matters. This is a clear executive departure of a director holding significant governance roles.
View raw filing on EDGAR →The 6-K discloses entry into a non-binding term sheet for a proposed acquisition of 100% of China Newlink Holding Limited for US$15 million in newly issued shares (5 million ADSs). Although non-binding, this represents a material M&A activity under Item 1.01 equivalent, involving a substantial transaction with the company's controlling shareholder (related-party transaction) and requiring Audit Committee review and fairness opinion. The transaction is material to investors assessing the registrant's strategic direction and capital allocation.
View raw filing on EDGAR →Z Squared Inc. completed an advance under its Standby Equity Purchase Agreement (SEPA) on June 26, 2026, issuing 1,302,806 shares of common stock to YA II PN, Ltd. at $11.8351 per share for gross proceeds of approximately $15.4 million. The shares were sold in reliance on Section 4(a)(2) exemption from registration, with resale registered under Form S-1.
View raw filing on EDGAR →Decoy Therapeutics entered into a Securities Purchase Agreement on June 26, 2026, for a private placement (PIPE) of common stock and warrants to raise approximately $3.5 million in upfront gross proceeds at $5.91 per share, plus up to $17.5 million in additional proceeds from milestone-based warrants. The unregistered securities are being issued under Section 4(a)(2) and Regulation D exemptions and will require a resale registration statement within 15 days of closing.
View raw filing on EDGAR →The 6-K discloses that Shinhan Financial Group is "currently reviewing various measures" including a potential acquisition of Lotte Insurance in response to media reports. While no decision has been finalized, the disclosure of active review of a material acquisition would affect a reasonable investor's assessment of the registrant's strategic direction and capital allocation. The matter does not fit cleanly into `ma_activity` (which typically covers completed, entered, or terminated transactions) because the acquisition remains under review with no finalized decision, but the materiality and strategic significance warrant classification as a material event rather than routine administrative disclosure.
View raw filing on EDGAR →Stockholders approved six proposals at the Annual Meeting held on June 26, 2026, including election of two Class III directors (Arvind Kush and Dennis Berman), ratification of CohnReznick LLP as auditor, amendments to the Certificate of Incorporation and 2020 Equity Incentive Plan, and advisory votes on executive compensation and voting frequency.
View raw filing on EDGAR →Korn Ferry entered into a definitive Sale and Purchase Agreement on June 27, 2026, to acquire all issued and outstanding shares of Auxey Holdco Limited (AMS) for approximately £850 million ($1.1 billion) in combined cash and stock consideration, creating a global leader in talent and organizational consulting with over 16,000 colleagues.
View raw filing on EDGAR →Verizon entered into a transaction agreement with BT Group plc to form a 50/50 joint venture (NewCo) by contributing its international wireline connectivity and managed network services business, along with a $625 million cash payment. This constitutes a material disposition and restructuring of a business segment that will result in estimated charges of $700–$800 million in Q2 2026, making it a significant M&A activity requiring disclosure under Item 1.01 or 2.01 principles, even though disclosed under Item 7.01.
View raw filing on EDGAR →The filing discloses delivery of Letters of Demand on June 18, 2026, stating that the Company's judicial management orders constitute Events of Default under three indentures governing approximately $1.5B+ in convertible notes (Variable-Rate, 9.00%, and Adjustable-Rate). The filing explicitly states that "due to the occurrence of these Events of Defaults, an automatic acceleration of the principal amount of, and all accrued and unpaid interest on, all 1st Lien Notes and 2nd Lien Notes has occurred," triggering immediate demands for full payment. This is a material covenant breach and acceleration event that directly threatens the Company's financial obligations and solvency, particularly given the Company is already under judicial management.
View raw filing on EDGAR →Larimar announced submission of the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp for Friedreich's ataxia, along with positive long-term open-label study data showing sustained skin frataxin (FXN) levels and directional clinical improvements. This is a material regulatory and clinical milestone for a clinical-stage biotech company, but does not fit neatly into the specific event categories (not an earnings release, M&A activity, impairment, or other defined types). The disclosure centers on a significant product development and regulatory advancement that would affect a reasonable investor's assessment of the company's progress toward commercialization.
View raw filing on EDGAR →Jonathan Collins was appointed as Senior Vice President, Finance and Chief Financial Officer of Genesco, effective August 3, 2026, following a comprehensive search process. Collins brings 30+ years of financial leadership experience, including prior roles at Walmart and America's Car-Mart. The appointment includes a base salary of $550,000, target incentive of $412,500, and long-term incentive target of $825,000.
View raw filing on EDGAR →The exhibit announces the appointment of Dr. Srishti Gupta as Chief Executive Officer and Board member of NovaBridge Biosciences, effective July 1, 2026. While the announcement also discloses that Xi-Yong (Sean) Fu is stepping down as CEO, the principal disclosed action is Gupta's appointment to the CEO role. The disclosure emphasizes her extensive leadership experience across biopharmaceuticals and global health, and the Board's confidence in her ability to advance the company's pipeline and create shareholder value—a material change in executive leadership at a clinical-stage biopharmaceutical company.
View raw filing on EDGAR →REGENXBIO announced receipt of a $100 million milestone payment from AbbVie triggered by dosing the first patient in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec. This is a material financial event—a substantial cash inflow tied to a contractual milestone under the September 2021 Collaboration and License Agreement. While the payment relates to clinical trial progress (operational), the primary disclosure centers on the financial obligation and cash receipt, making it a financial event rather than operational. It does not fit the specific categories of debt issuance, dividend distribution, or impairment, so financial_other is most appropriate.
View raw filing on EDGAR →Zymeworks entered into a definitive Agreement and Plan of Merger on June 28, 2026, to acquire Theravance Biopharma for $17.00 per share (approximately $929 million in total cash consideration), including contingent value rights tied to future product monetization. The transaction adds YUPELRI® and associated royalty streams to Zymeworks' portfolio.
View raw filing on EDGAR →CIM Real Estate Finance Trust (CMFT) completed a transformational acquisition of CIM Group, LLC's real assets management business and investment portfolio on June 24, 2026, resulting in a change of control where CIM Group, LLC received 67.5% voting and economic ownership of the combined entity. The company changed its legal name to CIM Group, Inc., ceased REIT status, and now operates as a diversified real assets manager with over $30 billion in assets under management.
View raw filing on EDGAR →David Thompson was appointed Chief Financial Officer, Principal Accounting Officer, and Treasurer of CIM Group, Inc. (formerly CMFT) effective June 24, 2026, replacing Nathan D. DeBacker. Thompson received an equity award of 30,433.658 RSUs under the 2024 Manager Plan.
View raw filing on EDGAR →This press release announces the integration of Saber Money into OwlPay Harbor, expanding OwlTing's cross-border payment infrastructure into India's US$860 billion export economy with direct rupee settlement and Eurozone/UK payment access. The disclosure describes a material operational and strategic milestone—opening a major new payment corridor and revenue opportunity—that aligns with management's stated 2026 objective of converting infrastructure into production client relationships and revenue. While not a discrete M&A transaction, the integration represents a significant expansion of the Company's addressable market and operational capabilities.
View raw filing on EDGAR →Strategy Inc announced a revised dividend policy for its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC) with a rate increase to 12.00% effective July 1, 2026, and declared conditional cash dividends for July 31 and August 15, 2026. The announcement also covers repurchase programs for preferred and common stock, a BTC monetization program, and a USD Reserve policy.
View raw filing on EDGAR →4D Molecular Therapeutics entered into a Loan and Security Agreement with Hercules Capital on June 24, 2026, establishing a new term loan facility of up to $200 million maturing June 1, 2031. The agreement includes specified interest rates, facility charges, covenants, and security interests.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of the 2026 Annual Meeting of Shareholders held on June 23, 2026. The filing presents detailed voting results for the election of eight directors and ratification of Weaver and Tidwell, L.L.P. as independent auditor, including vote counts (FOR, AGAINST, ABSTAIN, and broker non-votes) for each matter. Shareholder vote results are material to investors as they reflect governance outcomes and board composition.
View raw filing on EDGAR →Evommune announced that its Phase 2b clinical trial of EVO756 failed to meet its primary endpoint in chronic spontaneous urticaria, leading the company to cease development in this indication while continuing evaluation in atopic dermatitis and migraine. This material clinical development setback represents a significant strategic pivot affecting the company's pipeline and investor assessment of its progress.
View raw filing on EDGAR →JATT II Acquisition Corp entered into a definitive Business Combination Agreement with Talawar Tx Inc. on June 29, 2026, whereby Merger Sub will merge with and into JATT, with JATT surviving as a wholly-owned subsidiary of Talawar. The transaction involves $285 million in combined proceeds ($60 million from trust account plus $225 million PIPE financing) and is expected to close in H2 2026, with the combined entity listing on Nasdaq under ticker "TLWR."
View raw filing on EDGAR →This press release announces the completion of Optimi's third commercial psilocybin export shipment to Australia (1,000 capsules of 5mg psilocybin for treatment-resistant depression), marking ongoing commercial revenue generation from a regulated market. The disclosure emphasizes the company's commercial-stage operations, expanding reimbursement coverage from public and private insurers, and the absence of serious adverse events. While this is an operational milestone reflecting the company's ability to execute its business model in a regulated psychedelic medicine market, it does not fit the discrete event categories (M&A, earnings release, executive changes, debt issuance, etc.) and is best classified as an operational business development event.
View raw filing on EDGAR →The Company completed a forward sale offering of 14,000,000 shares of common stock on June 17, 2026, with an additional 2,100,000 shares issued via exercise of an underwriter option on June 26, 2026. This represents a dilutive equity issuance totaling 16.1 million shares at $23.12325 per share, generating substantial proceeds for the Operating Partnership. The forward sale structure with multiple underwriters and forward purchasers is characteristic of a large equity capital raise, which is material to existing shareholders.
View raw filing on EDGAR →Eric Hyllengren was appointed as Chief Financial Officer effective July 13, 2026, with responsibility for Principal Financial Officer and Principal Accounting Officer roles. The appointment includes compensatory arrangements consisting of a base salary of $490,000, a 40% target bonus, and an option grant of 1,650,000 shares.
View raw filing on EDGAR →Fortune Brands Innovations appointed Jesse G. Singh as Chief Executive Officer and Class I Board member effective June 29, 2026, following a comprehensive search process. David V. Barry was appointed Executive Vice President and Chief Operating Officer, transitioning from his interim CEO role. Singh's compensation package includes a base salary of $1,100,000, a bonus target of 150%, and a long-term incentive award of $6,700,000.
View raw filing on EDGAR →A. Jayson Adair was appointed as Chief Executive Officer effective July 31, 2026, succeeding Jeffrey Liaw. This represents a significant leadership change at the company.
View raw filing on EDGAR →The filing discloses the results of the 2026 annual meeting of stockholders held on June 26, 2026, which is the required Item 5.07 disclosure. Although the meeting failed to achieve quorum and was adjourned without conducting any business—including director elections and auditor ratification—this is still a shareholder vote result disclosure. The failure to achieve quorum and the resulting holdover director arrangement is material to investors as it affects board composition and governance continuity.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Virginia National Bankshares' 2026 Annual Meeting of Shareholders held on June 25, 2026, including voting outcomes for three proposals: (1) election of 11 directors, (2) advisory approval of executive compensation, and (3) ratification of the independent auditor Yount, Hyde & Barbour, P.C. The filing presents detailed vote tallies (votes for, against, withheld, and broker non-votes) for each director nominee and proposal, which is the standard format for shareholder vote results disclosures under Item 5.07.
View raw filing on EDGAR →The filing discloses a declared distribution of $0.1361 per common share by Fidelity Core Real Estate Fund, payable to shareholders of record on June 30, 2026, with payment on or about July 22, 2026. This is a routine but material dividend declaration for a real estate fund, which typically distributes income regularly to shareholders. The disclosure clearly falls under dividend_distribution.
View raw filing on EDGAR →The registrant conducted an unregistered private offering of 230,757.640 Class I common shares for approximately $4.7 million, relying on Section 4(a)(2) and Regulation D/S exemptions as part of a continuous offering.
View raw filing on EDGAR →The registrant declared a regular monthly distribution of $0.15 per share for Class I Shares, payable on or about July 9, 2026.
View raw filing on EDGAR →The Board of Directors has authorized a distribution to stockholders across multiple share classes (Class T, D, I, and X-1 common stock) with a record date of June 30, 2026 and payment date of approximately July 6, 2026. This is a routine but material dividend distribution to equity holders, disclosed under Item 8.01 (Other Events), with specific per-share amounts and distribution fees detailed for each class.
View raw filing on EDGAR →The filing discloses authorization by the board of directors of a distribution to stockholders of $0.1356 per share, payable on or about July 7, 2026, to shareholders of record as of June 30, 2026. This is a routine dividend distribution declaration by a real estate investment trust (REIT), which is material to investors as it affects shareholder returns and is a core component of REIT investor value propositions.
View raw filing on EDGAR →SPS issued $1.2 billion in aggregate principal amount of First Mortgage Bonds in two series (5.300% due 2036 and 5.875% due 2056) on June 29, 2026. This is a material creation of direct financial obligations governed by an indenture with a trustee, clearly constituting a debt issuance under Item 8.01 disclosure.
View raw filing on EDGAR →Zimmer Biomet entered into two new revolving credit facilities totaling $2.75 billion ($1.5 billion five-year and $1.25 billion 364-day) on June 26, 2026, and terminated two prior 2025 credit agreements. This refinancing materially affects the company's capital structure and liquidity position.
View raw filing on EDGAR →This press release announces a registered direct offering of 7,000,000 ADSs at $0.625 per share (gross proceeds ~$4.375 million) to a single institutional investor. The offering is registered under Form F-3 and represents a dilutive equity issuance. The company explicitly states it will use net proceeds for working capital and general corporate purposes, which is typical of capital-raising activity by smaller issuers. This is material to investors as it increases share count and dilutes existing shareholders.
View raw filing on EDGAR →